Wells Fargo
PRME icon

Wells Fargo’s Prime Medicine PRME Stock Holding History

Wells Fargo’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.11M Buy
319,550
+25,054
+9% +$95.4K ﹤0.01% 3682
2025
Q4 		$1.02M Buy
294,496
+97,482
+49% +$434K ﹤0.01% 3953
2025
Q3 		$1.09M Buy
197,014
+95,863
+95% +$389K ﹤0.01% 3752
2025
Q2 		$250K Buy
101,151
+10,332
+11% +$15.9K ﹤0.01% 4638
2025
Q1 		$181K Sell
90,819
-5,362
-6% -$13.7K ﹤0.01% 4780
2024
Q4 		$281K Sell
96,181
-75,287
-44% -$264K ﹤0.01% 4578
2024
Q3 		$664K Buy
171,468
+151,110
+742% +$700K ﹤0.01% 3815
2024
Q2 		$105K Buy
20,358
+8,548
+72% +$51.8K ﹤0.01% 4914
2024
Q1 		$82.7K Buy
11,810
+1,581
+15% +$12K ﹤0.01% 5002
2023
Q4 		$90.6K Sell
10,229
-21,088
-67% -$162K ﹤0.01% 4968
2023
Q3 		$299K Buy
31,317
+15,020
+92% +$195K ﹤0.01% 4103
2023
Q2 		$239K Buy
16,297
+14,361
+742% +$200K ﹤0.01% 4476
2023
Q1 		$23.8K Buy
+1,936
New +$31.5K ﹤0.01% 5567

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Wells Fargo's PRME Position: Q1 2026 in Review

Wells Fargo increased its Prime Medicine (PRME) stake by 8.5% in Q1 2026, buying an estimated $95.4K and bringing the position to 319,550 shares worth $1.11M. The position accounts for ﹤0.01% of the portfolio, ranked #3682.

Wells Fargo first reported a position in PRME in Q1 2023 and has held it in 13 quarters since. 192 funds tracked by Wall St. Rank hold PRME as of Q1 2026.

  • Wells Fargo held 319,550 shares of Prime Medicine worth $1.11M as of Q1 2026.
  • Wells Fargo bought 25,054 Prime Medicine shares in Q1 2026, an estimated $95.4K.
  • Prime Medicine made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #3682 holding.
  • Wells Fargo first reported a position in Prime Medicine in Q1 2023 and has held it in 13 quarters since.
  • 192 funds tracked by Wall St. Rank held Prime Medicine as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.